Evaluation of the risk of post-operative bleeding complications in XXXX surgery without interruption of anticoagulant/antithrombotic medication: A prospective cohort study.

@entity1 @entity5 @entity1489 @entity957 @entity86 @entity1129 @entity320 @entity1491
BACKGROUND: Previous reports showed lack of consensus concerning interruption of anticoagulant/antithrombotic (AC/ @entity1129 ) treatment before @entity1489 surgery. AIM: The aim of this study was to evaluate the risk of @entity86 in @entity1 on AC/ @entity1129 treatment undergoing @entity1489 surgery without interruption of this treatment. METHOD: This prospective cohort study included 271 consecutive @entity1 divided into two groups - @entity1 without and @entity1 with AC/ @entity1129 therapy. Inclusion criteria were @entity1489 ( @entity1491 , @entity957 , or @entity320 ). Exclusion criteria were @entity1 undergoing regional lymph node dissection or sentinel lymph node biopsy. @entity86 complications taken into consideration were those evaluated as moderate or severe and requiring some form of surgical or non-surgical hemostasis on an outpatient or inpatient basis. RESULTS: There were 47 @entity1 in the AC/ @entity1129 group and 224 in the control group (mean age = 76.6 and 68 years, respectively), with almost equal distribution of @entity5 in both groups. There were 34.1% of @entity1 on @entity1129 , 55% on AC treatment, and 10.6% on mixed treatment (AC+ @entity1129 or @entity1129 + @entity1129 ). @entity86 complications did not show a statistically significant difference between the two groups (p = 0.063). CONCLUSION: @entity1489 surgery can be safely performed without discontinuation of AC/ @entity1129 treatment, since the risk of @entity86 is statistically insignificant.
